C. Denkert

352P Long-term survival of HER2-positive breast cancer patients with brain metastases: Final analysis of the Brain Metastases in Breast Cancer Registry (BMBC)

Philipp H. von Kroge, TW Park-Simon, Martina Schmidt, V. Mueller et autres

de (code pays fourni par la source)

78P Validation of an AI-based solution for breast cancer risk stratification using digital H&E images: Subgroup analysis within PANTHER clinical trial

Evangelos Tzoras, Dimitrios Salgkamis, Nikos Tsiknakis, Hemming Johansson et autres

The Nottingham histologic grade (NHG) 2 constitutes a gray zone within ER+ HER2- breast cancer (BC) with uncertain clinical significance. Stratipath Breast is a commercially available AI-based solution for prognostic risk stratification of BC using hematoxylin and eosin (H&E) whole slides imaging. …

se, de (code pays fourni par la source)

ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

P. Schmid, M.F. Mosele, Giancarlo Pruneri, H.J. Burstein et autres

us (code pays fourni par la source)

435 (PB423): Persistence of BRCA1 and RAD51C methylation after neoadjuvant chemotherapy in high risk TNBC

Stephen J. Pettitt, Paula Proszek, Gonzalo Torga, A. Gulati et autres

ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

P. Tarantino, Giulia Viale, Michael F. Press, Xin Hu et autres

us, it, cn, fr, gr, ch, es, de, gb, au (code pays fourni par la source)

Corrections to “PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab”

S. Loibl, I. Majewski, Valentina Guarneri, V. Nekljudova et autres

fr, de, nl, it, gb, us, ch, be, au (code pays fourni par la source)

Correction to: PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

S. Loibl, I. Majewski, Valentina Guarneri, V. Nekljudova et autres

Ann Oncol 2016; 27: 1519–1525 (doi: 10.1093/annonc/mdw197) In the original article, the following funding information was omitted: This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. This has now been added. PIK3CA mutations are associated with …